GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy

Inclusion Criteria: 1. Age ≥ 2 years and ≤ 12 years, gender not limited; 2. Meet the clinical diagnostic criteria for type 2 SMA, have an onset age form 6 months to 18 months, are diagnosed with SMN1 double allele pathogenic mutation, have 2-4 copies of SMN2 gene, and meet the clinical diagnostic criteria for SMA 5qSMA; 3. Capable of sitting alone but has never acquired the ability to walk independently (according to HFMSE standards, sitting alone: able to maintain a sitting position without hand support and count to 3 or more; walking independently: able to walk 4 or more steps without assistance); 4. The guardians of the subjects are able to understand and willing to comply with the requirements and procedures of protocol, voluntarily participate and sign the informed consent form. Exclusion Criteria: 1. Researchers believe that gene replacement therapy may cause unnecessary risk of concomitant diseases, such as serious cardiovascular and cerebrovascular diseases, digestive tract diseases, liver and kidney dysfunction diseases, diabetes, known epilepsy, convulsions, convulsions or family history of psychosis; 2. Subjects who have participated in AAV gene therapy or have participated in or are currently participating in clinical trials of other SMA drugs; 3. Received treatment with Nordenafil Sodium Injection within 4 months prior to administration; 4. Received treatment with risperidone within 15 days prior to administration; 5. Subjects who have been treated with β 2 receptor agonists within 30 days prior to treatment (excluding inhaled salbutamol); 6. Subjects with allergic constitution, including those who are allergic or hypersensitive to prednisolone, other glucocorticoids or their excipients, and allergic to local anesthetics; 7. During the screening period, non-invasive ventilation support should be used for at least 12 hours per day; 8. The serum Anti-AAV9 neutralizing antibody titer is greater than 1:200.